Zibotentan (ZD4054) is an anti-cancer candidate. It is an endothelin receptor antagonist.It failed a phase III clinical trial for prostate cancer but other trials are planned. Tolerability of zibotentan plus docetaxel has been evaluated.
This page contains content from the copyrighted Wikipedia article "Zibotentan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.